Lead Product(s) : Nangibotide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inotrem Reaches Agreement with FDA for Phase 3 Trial of Nangibotide in Septic Shock
Details : LR12 (nangibotide) targets the immunoreceptor TREM-1 (triggering receptor expressed on myeloid cells-1). It is under phase 2 clinical development for the treatment of Septic Shock.
Product Name : LR12
Product Type : Peptide
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : Nangibotide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nangibotide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nangibotide is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response and improve post septic shock survival. ASTONISH demonstrates that TREM-1 modulation with nangibotide improves respiratory, cardiovascular and renal...
Product Name : LR12
Product Type : Peptide
Upfront Cash : Inapplicable
October 13, 2022
Lead Product(s) : Nangibotide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nangibotide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inotrem Reports Interim Futility Analysis for Its Phase IIB ASTONISH Trial
Details : The ASTONISH Phase IIB study aims at demonstrating safety and clinical efficacy of nangibotide in septic shock patients. It is a global, multicentric study conducted in 48 centers.
Product Name : LR12
Product Type : Peptide
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : Nangibotide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nangibotide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Roche Diagnostics GmbH
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Inotrem Secures Strategic Licensing Agreement for a Companion Diagnostics Test in Septic Shock
Details : Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.
Product Name : LR12
Product Type : Peptide
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Nangibotide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Roche Diagnostics GmbH
Deal Size : Undisclosed
Deal Type : Licensing Agreement